Researchers at Guangzhou Salustier Biosciences Co. Ltd. and Jinan University (Guangdong) have identified selenium-containing heterocyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Biogen Inc. has synthesized non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of cancer, autoimmune disease, cardiovascular disorders, fibrosis, inflammatory disorders, liver diseases, pain and neurodegeneration, among others.
Presage Biosciences Inc. has announced that the FDA has issued a study may proceed notification for testing a pre-GMP drug candidate with the company’s Comparative In Vivo Oncology (CIVO) platform. Owned by Pure Biologics, the drug candidate, PBA-0405, is a ROR1-targeting compound that has been engineered to induce tumor cell killing by cytotoxic immune cells.
Solid Biosciences Inc.’s SGT-003 has been granted orphan drug designation by the FDA. The company’s next-generation Duchenne muscular dystrophy gene therapy candidate was also granted fast track designation last month.
E-Therapeutics plc has offered a pipeline update, following the nomination of novel target genes, which have yielded promising results in preclinical studies.
The stress-responsive protein PPP1R15A (protein phosphatase 1, regulatory subunit 15 A) promotes the unfolded protein response and restores protein homeostasis.
N4 Pharma plc’s subsidiary Nanogenics Ltd. has signed a contract to start the formulation and sequence selection work to prepare its ECP-105 product for testing in preclinical studies.
RSS
